MedTrace Logo

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

NCT06712017 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-12-05

No results posted yet for this study

Summary

Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China. Therefore, this retrospective real-world study is intented to explore the characteristics and efficacy of HCC patients treated with y90 in China, aiming to provide reference for guiding and optimizing clinical practices and subsequent confirmatory clinical studies for the treatment of HCC patients in China.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Hepatocellular Carcinoma Non-Resectable

Interventions

DEVICE

Yttrium-90 (Y-90) resin microspheres

selective internal radiation therapy

Sponsors & Collaborators

  • GrandPharma (China) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaobin Feng, MD · Beijing Tsinghua Changgeng Hospital

  • Kangshun Zhu, MD · Second Affiliated Hospital of Guangzhou Medical University

  • Yefa Yang, MD · The Third Affiliated Hospital of Naval Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06712017 on ClinicalTrials.gov